Drug Profile


Alternative Names: ICX-RHY-013; Vavelta

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercytex
  • Class Fibroblast cell therapies; Skin disorder therapies
  • Mechanism of Action Collagen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Phase II Epidermolysis bullosa
  • Suspended Scars

Most Recent Events

  • 17 Jul 2017 ICX RHY is still in phase II trials for Epidermolysis bullosa in United Kingdom
  • 06 Jul 2016 ICX RHY licensed to Knight Therapeutics for marketing in Canada, Israel, Russia and sub-Saharan Africa, Romania and the Caribbean
  • 16 Mar 2016 Ember Therapeutics acquires ICX RHY from Intercytex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top